drugset / Trial / NCT00328120
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer
Timeline
- Start
- 2004-04
- Primary completion
- 2006-04
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |